Fig. 1 | Laboratory Investigation

Fig. 1

From: Human relaxin-2 attenuates hepatic steatosis and fibrosis in mice with non-alcoholic fatty liver disease

Fig. 1

Relaxin-2 improved hepatic steatosis and increased expression of phosphorylated endothelial nitric oxide synthase (p-eNOS) in mice fed a high-fat diet (HFD). a Hematoxylin and eosin (H&E) and Oil Red O staining of liver. Scale bar = 50 μm. b Quantification of the area stained by Oil Red O. c Hepatic triglyceride (TG) content. d Serum human relaxin-2 levels. e Western blots of relaxin/insulin-like family peptide receptor 1 (RXFP1) in livers. Loading protein: 40 μg/lane. f Hepatic nitrate/nitrite (NOx) levels and western blots of phosphorylated and total endothelial nitric oxide synthase (p/t-eNOS) in liver extracts. Loading protein/lane: 80 μg. N-V/N-R75: normal mice receiving vehicle or relaxin-2 (75 μg/kg/day); HFD-V/HFD-R25/HFD-R75: HFD-fed mice treated with vehicle or relaxin-2 (25 or 75 μg/kg/day). (#p < 0.05 vs. N-V; ##p < 0.01 vs. N-V; *p < 0.05 vs. HFD-V)

Back to article page